JP2018530315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530315A5 JP2018530315A5 JP2018510813A JP2018510813A JP2018530315A5 JP 2018530315 A5 JP2018530315 A5 JP 2018530315A5 JP 2018510813 A JP2018510813 A JP 2018510813A JP 2018510813 A JP2018510813 A JP 2018510813A JP 2018530315 A5 JP2018530315 A5 JP 2018530315A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- fusion protein
- btx
- seq
- toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims 30
- 102000037865 fusion proteins Human genes 0.000 claims 30
- 108030001720 Bontoxilysin Proteins 0.000 claims 24
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims 23
- 101710194807 Protective antigen Proteins 0.000 claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 230000005945 translocation Effects 0.000 claims 18
- 239000003053 toxin Substances 0.000 claims 17
- 231100000765 toxin Toxicity 0.000 claims 17
- 108700012359 toxins Proteins 0.000 claims 17
- 108030001722 Tentoxilysin Proteins 0.000 claims 13
- 108020003175 receptors Proteins 0.000 claims 13
- 102000005962 receptors Human genes 0.000 claims 13
- 210000000929 nociceptor Anatomy 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 8
- 108010055044 Tetanus Toxin Proteins 0.000 claims 7
- 210000004899 c-terminal region Anatomy 0.000 claims 7
- 241000193738 Bacillus anthracis Species 0.000 claims 6
- 241001112695 Clostridiales Species 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 102000004961 Furin Human genes 0.000 claims 4
- 108090001126 Furin Proteins 0.000 claims 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 4
- 230000003197 catalytic effect Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108091005804 Peptidases Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 210000001163 endosome Anatomy 0.000 claims 3
- 108091008700 nociceptors Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102100031325 Anthrax toxin receptor 2 Human genes 0.000 claims 2
- 101000796085 Homo sapiens Anthrax toxin receptor 2 Proteins 0.000 claims 2
- 102000000583 SNARE Proteins Human genes 0.000 claims 2
- 108010041948 SNARE Proteins Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000000172 cytosol Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- XUNKPNYCNUKOAU-VXJRNSOOSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]a Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUNKPNYCNUKOAU-VXJRNSOOSA-N 0.000 claims 1
- 101500000960 Bacillus anthracis Protective antigen PA-63 Proteins 0.000 claims 1
- 101100406366 Caenorhabditis elegans pad-2 gene Proteins 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 229940053031 botulinum toxin Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000012202 endocytosis Effects 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000003040 nociceptive effect Effects 0.000 claims 1
- 231100000065 noncytotoxic Toxicity 0.000 claims 1
- 230000002020 noncytotoxic effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 229940118376 tetanus toxin Drugs 0.000 claims 1
- 230000017105 transposition Effects 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210610P | 2015-08-27 | 2015-08-27 | |
| US62/210,610 | 2015-08-27 | ||
| PCT/US2016/049099 WO2017035507A1 (en) | 2015-08-27 | 2016-08-26 | Compositions and methods for treatment of pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018530315A JP2018530315A (ja) | 2018-10-18 |
| JP2018530315A5 true JP2018530315A5 (https=) | 2019-10-03 |
Family
ID=58101095
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511085A Pending JP2018525021A (ja) | 2015-08-27 | 2016-08-26 | 疼痛の治療を目的とする組成物及び方法 |
| JP2018510813A Pending JP2018530315A (ja) | 2015-08-27 | 2016-08-26 | 疼痛の治療を目的とする組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511085A Pending JP2018525021A (ja) | 2015-08-27 | 2016-08-26 | 疼痛の治療を目的とする組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10704035B2 (https=) |
| EP (2) | EP3341392A4 (https=) |
| JP (2) | JP2018525021A (https=) |
| KR (2) | KR20180070563A (https=) |
| CN (2) | CN108350039A (https=) |
| AU (2) | AU2016312685A1 (https=) |
| BR (2) | BR112018003782A2 (https=) |
| CA (2) | CA2994729A1 (https=) |
| EA (1) | EA201890587A1 (https=) |
| MX (1) | MX2018002183A (https=) |
| WO (2) | WO2017035507A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220354962A1 (en) * | 2015-05-12 | 2022-11-10 | The Trustees Of The University Of Pennsylvania | Rapid production of bispecific antibodies from off-the-shelf iggs with high yield and purity |
| TW201718627A (zh) * | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| BR112018003782A2 (pt) | 2015-08-27 | 2018-09-25 | Ipsen Pharma Sas | composições e métodos para o tratamento da dor |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3481852B1 (en) * | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| WO2019067815A2 (en) * | 2017-09-29 | 2019-04-04 | Children's Medical Center Corporation | NEUROTOXIN-LIKE TOXIN AND USES THEREOF |
| TWI822723B (zh) | 2018-01-29 | 2023-11-21 | 英商艾普森生物製藥有限公司 | 非神經元性 SNARE 裂解的肉毒桿菌神經毒素、裂解 hSNAP-23 之活體外方法、及經修飾 BoNT/A L 鏈蛋白酶之用途 |
| US11707510B2 (en) * | 2018-02-16 | 2023-07-25 | Preclinics Discovery Gmbh | Nucleic acid-based botulinum neurotoxin for therapeutic use |
| CA3101481A1 (en) * | 2018-05-30 | 2019-12-05 | The Governing Council Of The University Of Toronto | Methods and kits for identifying a protein associated with receptor-ligand interactions |
| EP3825333A4 (en) * | 2018-07-06 | 2022-04-06 | Abmax Biopharmaceuticals | LOW FUNCTIONALITY ADCC/CDC MONOCLONAL ANTIBODY, METHOD FOR PREPARATION AND USE |
| WO2020024002A1 (en) * | 2018-07-31 | 2020-02-06 | Snoretox Pty Ltd | Pegylated tetanus neurotoxins and treatment of hypotonia |
| WO2020116686A1 (ko) * | 2018-12-06 | 2020-06-11 | 고려대학교 산학협력단 | 인간 항-antxr 키메라 항원 수용체 및 이의 용도 |
| EP4093434A4 (en) * | 2020-01-21 | 2024-06-26 | Trustees of Dartmouth College | Immunologically optimized botulinum toxin light chain variants |
| EP4100038A4 (en) | 2020-02-03 | 2024-02-28 | Premas Biotech Private Limited | RECOMBINANT EXPRESSION PLATFORM, CONSTRUCTS AND METHODS FOR EXPRESSING HARD-TO-EXPRESS PROTEINS (DTE-PS) |
| WO2021173916A1 (en) * | 2020-02-27 | 2021-09-02 | President And Fellows Of Harvard College | Nociceptor neurons control cancer immunosurveillance |
| GB202104294D0 (en) * | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| KR102728382B1 (ko) * | 2022-10-12 | 2024-11-14 | 주식회사 알케미어 | 보툴리눔 독소의 경쇄 변이체 |
| CN120699106A (zh) * | 2024-03-26 | 2025-09-26 | 广州锡滔生物医药科技有限公司 | 一种多肽及其应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| EP0866718A1 (en) | 1995-12-13 | 1998-09-30 | President And Fellows Of Harvard College | Use of toxin peptides and/or affinity handles for the delivering compounds into cells |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| US6365185B1 (en) | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
| AUPP627498A0 (en) | 1998-10-02 | 1998-10-22 | University Of Queensland, The | Novel peptides - i |
| US6767896B1 (en) | 1999-01-29 | 2004-07-27 | Cognetix, Inc. | Conotoxin peptides |
| ATE348178T1 (de) * | 1999-08-25 | 2007-01-15 | Allergan Inc | Aktivierbare rekombinante neurotoxine |
| AU771632B2 (en) * | 1999-09-24 | 2004-04-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| WO2001049312A2 (en) | 1999-12-30 | 2001-07-12 | University Of Utah Research Foundation | O-superfamily conotoxin peptides |
| JP2006507800A (ja) * | 2002-06-07 | 2006-03-09 | ラージ・スケール・バイオロジー・コーポレイション | 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| WO2006096515A2 (en) | 2005-03-04 | 2006-09-14 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| ATE518882T1 (de) | 2005-09-19 | 2011-08-15 | Allergan Inc | Mit clostridientoxin aktivierbare clostridientoxine |
| JP2009514545A (ja) | 2005-11-08 | 2009-04-09 | アテリス ラボラトリーズ | μ−コノトキシンぺプチドおよびμ−コノトキシンぺプチドの局所麻酔薬としての使用 |
| EP2001902B1 (en) | 2006-03-14 | 2013-03-27 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| AU2007272515B2 (en) | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| WO2008008805A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| US9284358B2 (en) | 2006-07-18 | 2016-03-15 | University Of Utah Research Foundation | Conotoxin peptides |
| WO2012096926A2 (en) | 2011-01-10 | 2012-07-19 | President And Fellows Of Harvard College | Method for delivering agents into cells using bacterial toxins |
| GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| CA2865243A1 (en) | 2012-02-23 | 2013-08-29 | President And Fellows Of Harvard College | Modified microbial toxin receptor for delivering agents into cells |
| WO2013177231A1 (en) | 2012-05-21 | 2013-11-28 | Massachusetts Institute Of Technology | Translocation of non-natural chemical entities through anthrax protective antigen pore |
| US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| WO2014088928A1 (en) | 2012-12-03 | 2014-06-12 | President And Fellows Of Harvard College | Methods for making targeted protein toxins by sortase-mediated protein ligation |
| GB201407525D0 (en) | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| BR112018003782A2 (pt) | 2015-08-27 | 2018-09-25 | Ipsen Pharma Sas | composições e métodos para o tratamento da dor |
-
2016
- 2016-08-26 BR BR112018003782A patent/BR112018003782A2/pt not_active Application Discontinuation
- 2016-08-26 BR BR112018003794A patent/BR112018003794A2/pt not_active Application Discontinuation
- 2016-08-26 MX MX2018002183A patent/MX2018002183A/es unknown
- 2016-08-26 CA CA2994729A patent/CA2994729A1/en not_active Abandoned
- 2016-08-26 CA CA2994560A patent/CA2994560A1/en not_active Abandoned
- 2016-08-26 CN CN201680062362.0A patent/CN108350039A/zh active Pending
- 2016-08-26 CN CN201680062855.4A patent/CN108602861A/zh active Pending
- 2016-08-26 WO PCT/US2016/049099 patent/WO2017035507A1/en not_active Ceased
- 2016-08-26 AU AU2016312685A patent/AU2016312685A1/en not_active Abandoned
- 2016-08-26 WO PCT/US2016/049106 patent/WO2017035508A1/en not_active Ceased
- 2016-08-26 US US15/755,543 patent/US10704035B2/en active Active
- 2016-08-26 KR KR1020187008538A patent/KR20180070563A/ko not_active Withdrawn
- 2016-08-26 AU AU2016310521A patent/AU2016310521A1/en not_active Abandoned
- 2016-08-26 KR KR1020187008537A patent/KR20180050679A/ko not_active Withdrawn
- 2016-08-26 EP EP16840235.2A patent/EP3341392A4/en active Pending
- 2016-08-26 JP JP2018511085A patent/JP2018525021A/ja active Pending
- 2016-08-26 US US15/755,544 patent/US11753633B2/en active Active
- 2016-08-26 JP JP2018510813A patent/JP2018530315A/ja active Pending
- 2016-08-26 EA EA201890587A patent/EA201890587A1/ru unknown
- 2016-08-26 EP EP16840234.5A patent/EP3341391A4/en active Pending
-
2020
- 2020-05-27 US US16/884,893 patent/US11104892B2/en active Active
-
2021
- 2021-08-13 US US17/402,323 patent/US20220033795A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530315A5 (https=) | ||
| JP2018525021A5 (https=) | ||
| Löwenadler et al. | A gene fusion system for generating antibodies against short peptides | |
| KR102567311B1 (ko) | 보툴리눔 신경독소의 정제 및 활성화 방법 | |
| Futaki et al. | Arginine carrier peptide bearing Ni (II) chelator to promote cellular uptake of histidine-tagged proteins | |
| JP2019521643A5 (https=) | ||
| WO2017132580A2 (en) | Split inteins with exceptional splicing activity | |
| JP2005120106A5 (https=) | ||
| KR102040982B1 (ko) | 고용해성 녹색형광 단백질과 보툴리늄 독소 단백질의 융합단백질 구성을 통한 재조합 보툴리늄 독소 단백질의 대량생산 기술 | |
| US6379903B1 (en) | Purification of recombinant proteins fused to multiple epitopes | |
| IL294059A (en) | Mutant rsv f protein and its use | |
| CA2636075A1 (en) | Chimaeric fusion protein with superior chaperone and folding activities | |
| US10633643B2 (en) | Engineered Clostridium botulinum toxin adapted to deliver molecules into selected cells | |
| CA2344993A1 (en) | Method for the production of (poly)peptides by using truncated variants of the sv40 large t antigen with an intact n terminus | |
| US20190077829A1 (en) | Methods and compositions to increase the rate of ligation reactions catalyzed by a sortase | |
| Iwamoto et al. | Synthetic studies on the extracellular domain of the T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) using Trt-K10 solubilizing tags | |
| JP5757639B2 (ja) | セルピンフィンガー融合ポリペプチド | |
| Murby et al. | Differential degradation of a recombinant albumin‐binding receptor in Escherichia coli | |
| WO2004056316A3 (en) | Vaccines against hiv-1 tat protein to generate neutralizing antibodies | |
| Gruschke et al. | Peptides from the SARS-associated coronavirus as tags for protein expression and purification | |
| WO2005062871A3 (en) | Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays | |
| HK40007330A (en) | Method for purification and activation of botulinum neurotoxin | |
| NZ733789B2 (en) | Binding-triggered transcriptional switches and methods of use thereof | |
| HK40006631B (en) | Method for purification and activation of botulinum neurotoxin | |
| WO1999002706A1 (en) | Glycosylation peptides |